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Chapter I 
 
INTRODUCTION 
 
G-protein Coupled Receptors 
 
Acetylcholine (ACh) is a neurotransmitter widely involved in the regulation of many 
physiological processes and functions. It plays important roles in both the central nervous system 
(CNS) and peripheral nervous system (PNS). In the periphery, ACh is released in areas such as 
the neuromuscular junctions, parasympathetic and sympathetic synapses. It is involved in 
cardiovascular functions, muscle contractions, and many others. In the CNS, acetylcholine is 
localized in various parts of the brain, and it is responsible for the regulation of functions such as 
learning, attention, memory, movement, and many others. 
Acetylcholine activates two families of ionotropic receptors, the nicotinic and muscarinic 
cholinergic receptors. Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated 
ion channels that can be activated by exogenous nicotine.1 Upon the binding of two acetylcholine 
molecules, the receptor undergoes conformational changes. These conformational changes 
trigger the opening of a channel and allow the exchanges of ions such as Ca2+ and Na+. 
Muscarinic acetylcholine receptors (mAChRs) are G-protein coupled receptors (GPCR) that 
mediate metabotropic signaling of acetylcholine2. There exist five different subtypes (M1- M5) 
that are differentially expressed in the periphery and CNS.2 
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Figure 1. General distribution of muscarinic acetylcholine receptors (mAChRs) in the human brain.  
 
GPCRS are G-protein coupled receptors that bind to a G-protein upon activation by an 
agonist. Once bound to G-protein, the Gα subunit on the G-protein is activated to release GDP 
and bind GTP. Gα activation initiates a chain of signal transduction that could stimulate the 
production of a second messenger or induce interactions with downstream effectors. There are 
three different classes of GPCRs: A, B, and C or type I, II, or III.2 These classifications are based 
on the location of their orthosteric binding domain.2 However, all three classes have one 
common structural morphology, they all have seven helical domains that span the 
transmembrane region. Structurally, mAChRs are classified as class A, or type I, rhodopsin-like 
GPCRs, which has its orthosteric binding site that is embedded in the hydrophobic core of the 
transmembrane domains (Figure 2).2 Class B has its orthosteric site that flanks the short 
extracellular N-terminus.2 Class C typically exists as a dimer with its orthosteric site flanking the 
long, extracellular, venus flytrap N terminus.2 
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Figure 2. Classes of GPCRs. Class A: orthosteric site is within the transmembrane region. Class B: orthosteric site 
is located at the periphery on the N-terminus. Class C: orthosteric site is within the large N-terminus.2 
 
Allosteric modulation of GPCRs 
 
 
 GPCRs are the largest class of cell-surface receptors and play crucial roles in every organ 
system. Ligands such as hormones, neurotransmitters, ions, odorants, photons, and various 
signaling molecules can activate a wide range of GPCRs. They have been implicated in a wide 
range of disorders. Most modern drugs regulate GPCR activity. Despite past successes of GPCRs 
as drug targets, there’s a limited number of useful ligands that are specific to each type of 
receptor. There are more than 1000 genes encoded for GPCRs; however, there exist ligands only 
for a small fraction of these receptors.4 The search for highly selective tool compounds for this 
class of receptors is strenuous and often results in failure. Ligands that are not specific could lead 
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to off-target activities that may have detrimental effects. Therefore, it is important to develop 
ligands that are highly specific for their targets. Selective ligands are difficult to develop mainly 
due to high structural homology of the orthosteric site across the members within a single GPCR 
subfamily making it difficult to achieve selectivity for each subtype. To combat this problem, 
selective modulators that target an allosteric site, a site other than the orthosteric site, are 
explored. This has shown to be successful for ligand-gated ion channels4. These molecules bind 
and act at a site that is distinct from the orthosteric site. These ligands can either potentiate or 
inhibit activation of the receptor by its natural ligand. An example of this alternate approach to 
obtain better selectivity is Benzodiazephines, which are positive allosteric modulators of gama-
aminobutyric acid (GABA) A receptors used for the treatment of anxiety and sleep disorders.4 
By targeting the GABA receptors allosterically, the lethal affects of acting at the receptor 
directly as agonists are circumvented.  
 
Modes of action of allosteric ligands 
 Allosteric modulators have a wide range of activities such as positive allosteric modulation 
(PAM), which enhances the response of the receptor to its endogenous agonists, negative 
allosteric modulation (NAM), which reduces the responsiveness of receptors, and neutral 
ligands, which binds to the allosteric site but have no effects on the response of the orthosteric 
ligand4. In recent years, progress has been made in the development PAMs, NAMs, and neutral 
ligands for each of the three major classes of GPCRs: A, B, and C.4 These allosteric modulators 
provide new modes of action compared to the orthosteric ligands. 
 Allosteric modulators bind to GPCRs at sites that are topographically distinct from the 
orthosteric site thereby inducing novel receptor conformational changes.4, 5, 6, 7 As a result the 
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action of the orthosteric ligands on the receptor and any downstream signaling can be altered. 
This mechanism of action can alter receptor activity positively, or negatively. Allosteric 
modulators can exhibit some of the following pharmacological properties: affinity modulation- 
the orthosteric binding pocket can be impacted such that the association, dissociation rate, or 
both rates of the orthosteric ligand is modified; efficacy modulation- intracellular responses can 
be altered leading to a change in the intrinsic efficacy of the orthosteric ligand; agonism/inverse 
agonism- the allosteric modulator can modulate the receptor activation positively or negatively 
irrespective of the presence of the orthosteric ligand.4, 5, 6, 7 Allosteric mechanisms are governed 
by the affinity of the modulator and the cooperativity factors.4, 5 The potency of an allosteric 
ligand is dictated by its affinity for the receptor and its cooperativity with the orthosteric ligand4. 
 Allosteric modulators pose many advantages over orthosteric ligands. Those that do not on 
their own act as agonists do not display activity in the absence of endogenous orthosteric action.4, 
7
 They can only exert their effects in the presence of endogenous orthosteric ligands; the degree 
of their effect is limited to the concentration of endogenous ligand, hence, there is less target-
mediated toxicity due to high dosage because its efficacy.4, 7 Higher selectivity across receptor 
subtypes can be achieved easier with allosteric modulators due to the potential for higher 
sequence divergence between allosteric binding sites compared to the conserved orthosteric 
sites.4, 5, 6, 7 This higher selectivity could also be due to higher cooperativity between the 
allosteric site and orthosteric site in one subtype but lower cooperativity in another subtype.4, 5, 7 
Selectivity can also be produced by creating a ‘bitopic’ ligand that possesses both orthosteric and 
allosteric pharmacophores.4 These modulators are able to modify specific signaling pathways 
associated with a given GPCR to varying degrees giving different output of efficacies. For 
example, the same ligand may have different efficacies mobilizing calcium and phosphorylating 
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an effector, though these two pathways are linked to one receptor.4 This allows for further fine-
tuning of intracellular signaling with allosteric modulators. 
 Several examples of this new mode of pharmacology exist in the drug market: Cinacalcet, a 
positive allosteric modulator (PAM) of calcium sensing receptor (CaSR) helps increase 
sensitivity to circulating calcium.4 CaSR is involved in regulating calcium homeostasis and renal 
calcium resorption, as well as in the maintenance of inositol triphosphate levels; Maraviroc, a 
NAM of the chemokine receptor CCR5, is used in the treatment of HIV.4 These discoveries 
provide strong proof of concept for the utility of allosteric modulators.4 
 
Muscarinic acetylcholine receptors 
There are five mAChR subtypes, M1-M5, distributed throughout the CNS and the periphery 
(Figure 3).9, 10 In the periphery, M1-M4 expression dominates; they are expressed in the heart, 
lungs, GI, salivary glands, muscle cells, and the autonomic nerves.9, 10 In the central nervous 
system, M1-M5 are localized in the cerebral cortex, hippocampus, striatum, thalamus, brain stem, 
cerebellum, substantia nigra, and the ventral tegmental area.9, 10 Regulation of these receptors has 
been implicated in many neurodegenerative diseases. 
These subtypes share structure homology with high conservation of the acetylcholine 
orthosteric binding site. Among these subtypes, they are further classified into two subgroups: 
M1, M3, & M5 in one group and M2 & M4 in another.9, 10 This classification is derived from 
similarities in their structural homology and signal transduction pathways. M1, M3, and M5 share 
the highest structural homology with each other, while M2 and M4 have the highest homology 
with one another. Functionally, M1, M3, and M5 are considered stimulatory receptors in that they 
exhibit the most similar signaling pathways of stimulating phospholipase C (PLC) and inositol 
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triphosphate (IP3) as a result increasing intracellular Ca2+ concentration via coupling with G-
protein Gq.9, 10 M2 and M4 are most similar to each other both structurally and functionally. They 
inhibit the production of cyclic adenosine monophosphate (cAMP) by attenuating adenylyl 
cyclase (AC) via Gi coupling (Figure 4).9, 10 
 
 
Figure 3.General location of mAChR subtypes in the body. Karl-Erik, Anderson. Discovery Medicine 8 (42), 118-124 
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Figure 4. General function of muscarinic acetylcholine subtypes M1- M5.9 
 
Muscarinic acetylcholine receptors (mAChRs) are involved in a wide variety of 
biological processes and diseases such as pain, Alzheimer’s, schizophrenia, diabetes, and 
obesity11. Numerous non selective mAChR agonists have advanced into clinical development 
and show efficacy in improving cognition and alleviating psychotic symptoms in patients with 
Alzheimer’s disease or schizophrenia. Symptoms of schizophrenia are thought to be alleviated 
by activation of the M1 or M4 receptor subtypes.20  
 
Therapeutic relevance: schizophrenia 
 
 
M4 has been found to be linked to a schizophrenic pathway.11 Throughout the 20th 
century, schizophrenia was believed to be a unitary illness with one cause, which is dopamine 
(DA) hyperactivity, and one treatment.11 Therefore, first and second generation antipsychotics 
were all antagonists of the D2 receptors, and they mostly address only the positive symptoms but 
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not the negative or cognitive symptoms. Due to this and large variability of the symptoms 
manifested by patients, this unitary pathology is no longer a valid paradigm.11 The current belief 
is that this illness is made up of distinct independent but overlapping symptoms that can be 
distinguished pharmacologically, and that there are multiple molecular pathways involved 
(Figure 5A).11 Excessive response of the pyramidal neuron induces psychosis.11, 12 The current 
theory is that dopamine, serotonin, glutamate, and acetylcholine signaling facilitates the neuronal 
circuits involved in inducing psychosis (Figure 5B).12 
A)    B)  
Figure 5. A) Overlapping symptoms. 11 B) Molecular pathway involved.12 
 
The rationale for treatments via modification of dopamine signaling came from the idea 
that many physiological processes having a cognitive, reward, motivational, emotional or motor 
component are regulated in some way by dopaminergic pathways located in the central nervous 
system.13, 14 It has been hypothesized that schizophrenia involves a biphasic dysregulation of 
dopamine signaling in which the subcortical mesolimbic dopamine pathways are overactive and 
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the mesocortical DA pathways are underactive.13, 14 This combination leads to a decrease in the 
prefrontal DA signaling. Frontal cortical regions functions involve working memory and 
executive functions.11, 12, 13, 14 Schizophrenic patients demonstrate abnormal prefrontal activation 
associated with impaired performance of cognitive tasks. Using DA antagonists to suppress over-
activity is beneficial in alleviating positive symptoms but it could further exacerbate negative 
and cognitive symptoms by further decreasing DA signaling in the frontal cortex.11, 14 DA 
agonists alleviate negative and cognitive impairments but exacerbates psychosis.11, 14 Studies 
have shown that in addition to regulating the dopamine receptor, regulation of the  NMDA 
receptor directly or indirectly through glutamate receptors, glyT1, or muscarinic acetylcholine 
receptors can be therapeutic.11,13  
 NMDA (N-methyl-D-aspartate) receptor is a type of ionotropic glutamate receptor. Its 
antagonists PCP, ketamine, or their analogs have been known to induce positive, negative, and 
cognitive symptoms of schizophrenia in healthy patients.11, 15 Clinical observations show that 
administering NMDA co-agonist, glycine, modestly improves these symptoms.15 These 
observations lead to the NMDA receptor hypothesis of schizophrenia. Agents that activate 
NMDA receptor directly or indirectly by modulating other receptors that activate NMDA could 
potentially improve symptoms of schizophrenia.15 Glycine is an agonist of the NR1 subunit of 
the NMDA receptor.15 It’s been shown that glycine improves the symptoms of schizophrenia. 
The Javitt lab demonstrated that glycine treatment leads to a significant decline of negative 
symptoms, a decline in positive symptoms and cognitive symptoms.15 Therefore, a potential 
approach to treatment is to increase extracellular glycine levels to increase NMDA activation by 
preventing its uptake. Synaptic level of glycine is regulated by glycine transporter 1 and 2.15 
GlyT1 inhibitors such as sarcosine have shown to improve positive, negative, and cognitive 
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symptoms of schizophrenia.15 The localization of GlyT1 mirrors the localization of  NMDA 
receptors suggesting that they are optimally localized to modulate glycine level at  NMDA-
receptor expressing synapses.15 
Metapotropic glutamate receptors (mGluRs) modulate glutamate signaling by pre and 
post-synaptic and glia mechanisms.16 Due to its modulatory role and distribution in the forebrain, 
they are implicated as potential targets for lowering brain excitability seen in various psychiatric 
disorders.16 Schizophrenia is associated with excessive glutamate release.16 Activation of 
mGluR2/3 decreases the release of glutamate.16, 17 PCP or phencyclidine and ketamine are agents 
that antagonize the NMDA receptor (a type of ionotropic glutamate receptor) and increases 
cortical excitability which results in the induction of psychosis.16 mGluR2/3 receptor agonists 
have been shown to block the activity of PCP and related drugs, in other words, they block  
NMDA antagonist activity.17 The Schoepp lab demonstrated that PCP increases locomotion in 
both wildtype and mice that lack mGluR2/3.17 mGluR2/3 agonists are able to block PCP-induced 
hyperlocomotion, which is a behavioral model of many neurological disorders including 
schizophrenia, in wildtype mice but not mice lacking mGluR2/3 receptors suggesting that these 
receptors are involved in PCP-induced locomotion.17 
To address negative and cognitive symptoms, muscarinic acetylcholine receptors are also 
compelling targets.11, 18, 19 Many studies support the idea of targeting muscarinic acetylcholine 
receptors for the treatment of schizophrenia. Felder and Wess used M1- M5 muscarinic receptor 
knockout mice to delineate the role of the muscarinic cholinergic subtypes.20 They demonstrated 
that hyperlocomotion increases in M1 and M4 knockout mice (Figure 6).20 This implicates the 
role of M1 and M4 subtypes in psychiatric disorders. 
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Figure 6. Effect of knockout mice on indicated properties.20 
 
M4 is localized in dopamine rich regions of the brain (mesolimbic and nigrostriatal 
dopaminergic pathways).21, 22, 23 Knockout studies in mice suggest that M4 regulates 
dopaminergic neurons that are involved in motor functions, cognition, and psychosis in these 
regions.21, 22, 23 M4 receptors are localized in brain regions thought to be involved in 
schizophrenia such as the cerebral cortex and limbic areas.21, 22, 23 To prove this, Felder et al. 
measured the effects of prepulse inhibition (PPI) of the acoustic startle response and locomotor 
activity, which are animal models of schizophrenia, in M4-knockout mice.24 The NMDA 
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antagonist, PCP, acts by stimulating locomotor activity and disrupting PPI (conditioned startle 
response- second startle response is lower than that of the first).24 In M4 knockout mice, it was 
discovered that locomotor activity increases and prepulse inhibition decreases, meaning that the 
startling response occurs unabeted even after the conditioned pulse.24 This result indicates that 
M4 activity is necessary in decreasing locomotor activity and increasing PPI (Figure 7).24 
 
 
 
                                  B)   
Figure 7. A) Effect of PCP on PPI in M4 knockout mice. B) Effect of PCP on hyperlocomotion in M4 knockout 
mice.24 
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To further establish the involvement of mAChRs in schizophrenia, Dean and Crook 
performed post mortem studies of the CNS in healthy individuals and unmedicated schizophrenic 
patients.25 Their findings suggest that the mRNA density of the M1 and M4 receptors is 
significantly lower in patients with schizophrenia compared to healthy patients.25 To further 
support the theory that muscarinic receptors play a role in schizophrenia, Raedler et al. observed 
muscarinic receptor occupancy in vivo in patients with schizophrenia.27 The following are 
SPECT brain images of healthy patients and schizophrenic patients (Figure 8).27 Muscarinic 
receptor occupancy is significantly less in patients with schizophrenia compared to normal 
subjects.27 
 
Figure 8. Muscarinic receptor occupancy in healthy patients and schizophrenic patients. Red = high receptor 
occupancy; blue = low receptor occupancy27. 
 
To support this muscarinic hypothesis even more, studies show that an M1/M4 preferring 
agonist, xanomeline, has antipsychotic efficacy. In large clinical trial studies of patients with 
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Alzheimer’s disease, xanomeline shows robust therapeutic effects in reducing psychosis and 
behavioral disturbances that are similar to those found in people with schizophrenia.27 In a study 
performed by Neil Bodick et al., an increasing concentration of xanomeline in patients improves 
symptoms such as delusions, wandering, vocal outburst, and hallucinations.28 Additional studies 
of xanomeline establish that it is efficacious in improving cognitive symptoms of schizophrenia. 
At high concentration of xanomeline, cognition and simple reaction time response improve.29 In 
a cognitive test battery, patients treated with xanomeline show the most robust improvement in 
measures of verbal learning, short-term memory function, list learning, story recall, delayed 
memory, and digit span tests (Figure 9).29 Xanomeline is unable to progress further in the 
clinical development process due to its lack of specificity. It is both M1 and M4 preferring, and it 
also has some affinity and efficacy at M2, M3, and M5; therefore, clinically it displays adverse 
peripheral effects expected from non-selective muscarinic agonists.28, 29, 30 
 
A) B)  
Figure 9. A) Effect of xanomeline in a cognitive test battery.29 B) Structure of xanomeline. 
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Following the clinical data obtained from xanomeline, significant efforts have been put 
forth in developing both M1 and M4 modifying agents. Due to the high structural homology of 
the muscarinic receptor subtypes, historical agonists such as oxotremorine and carbachol, and 
antagonists, such as atropine and scopolamine, are promiscuous towards these receptor subtypes. 
Hence, these non-selective ligands are not ideal as tool compounds (Figure 10)32. 
 
Agonists 
     
Carbachol    Oxotremorine 
Antagonists 
    
Atropine    Scopolamine 
Figure 10. Structures of historical agonists and antagonists. 
 
Recently, Chan and coworkers report a highly potent (EC50 < 100 nM) PAM called 
LY2033098 which has high selectivity for the human M4 mAChR.35 This compound also shows 
efficacy in paradigms predictive of antipsychotic drug efficacy such as reducing condition 
avoidance response and reversal of apomorphine-induced disruption of prepulse inhibition.35 
Due to its lower efficacy in the rat model, in in vivo studies, LY2033298 has to be co-dosed with 
oxotremorine in order for it to potentiate receptor function rendering it a less than ideal tool 
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compound.35 Major progress has been made in the discovery of selective allosteric modulators of 
M4. In addition to LY2033298, VU10010, VU0152099, and VU0152100 are reported as highly 
selective M4 PAMs (Figure 11).35, 36, 37 
VU10010   VU152099    VU0152100 
     
N S HN
O
NH2
O
 
EC50: 400 nM    EC50: 403 nM    EC50: 380 nM 
  
LY2033298 
Figure 11. Reported M4 PAMs. 
They all bind an M4 allosteric site and induce leftwards shifts in the ACh concentration 
response curve by increasing both the affinity and efficacy of ACh for the M4 receptor.35, 36, 37 
VU10010 displays no agonist activity in the absence of ACh; which differs than LY2033298 in 
that LY2033298 displays variable agonist activity on its own.35, 36 The development of analogs of 
VU10010 leads to the discovery of VU0152099 and VU0152100. Both are shown to have great 
efficacies and significantly reverse amphetamine-induced hyperlocomotion in rats.37 The 
discoveries of these modulators spur further research into the field of allosteric modulation of M4 
PAM in search for more selective and efficacious ligands that could be useful as tool compounds 
to further prove the involvement of M4 in schizophrenia. 
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Chapter II 
 
OPTIMIZATION AND CHARACTERIZATION OF M4 POSITIVE ALLOSTERIC 
MODULATORS 
 
 
Discovery of M4 PAM VU010010, VU0152099, and VU0152100 
 
Nomenclature of basic structure 
 
 
  
Figure 12. Nomenclature of basic structure. 
 
Discovery of VU1001036 
 The discovery of LY2033298 spurs extensive research in this field. We are able to identify 
a series of compounds with robust allosteric potentiation and high selectivity for the rat M4 
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receptor utilizing chemi-informatics and structure activity (SAR) methods. At the start of the M4 
project, we perform data mining of the ChemBridge database for compounds with similar core 
structures to LY2033298. 232 compounds are identified and tested for allosteric potentiator 
activity on M4 receptors in Chinese hamster ovary (CHO) cells stably expressing rM4 and the 
chimeric G protein Gqi5.36 This chimera allows for the immobilization of calcium, since M4 is not 
natively coupled to calcium. Gq activation initiates calcium mobilization, which is the readout 
that is typically used to monitor the direct effect of compounds on muscarinic acetylcholine 
receptors. The M4 receptor does not typically bind to Gq, therefore, it is necessary to generate a 
mutant receptor that allows for the binding of this G-proteins to induce an appropriate readout. 
The potentiation ability of the compound on an effective concentration of acetylcholine that 
induces 20% maximal response is determined by a functional fluorescence-based calcium assay. 
Out of the 232 compounds tested, several hits are identified. (Figure 13).36 On their own, these 
hits did not induce agonist response at M4. In the presence of acetylcholine, they enhance the 
response of the submaximal concentration of acetylcholine, indicating they are PAMs. 
 
     
7904200; EC50 =  6 µM       7911703; EC50 =  1.3 µM       7912361; EC50 =  395 nM 
Figure 13. Hits identified in screening of ChemBridge compounds purchased commercially.36 
 
 To determine the potency of each compound, cells are incubated with an increasing 
concentration of the test compound. Then an EC20 concentration of ACh is added to generate a 
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concentration response curve. It is noted that these compounds did not generate a clear efficacy 
plateau. The insolubility of these compounds prevented further testing at high concentration. 
 Next, the effect of a maximal concentration of these compounds on ACh CRC is 
determined. Cells are incubated with a fix concentration of the test compound that would 
generate a maximal response. Then increasing concentration of ACh is added. All of the above 
compounds (7904200, 7911703, 7912361) are tested, and they all cause a leftward shift of the 
ACh CRC, which is indicative of robust potentiation of the agonistic effect of ACh on the M4 
receptor.36 It indicates that a lower concentration of ACh is need for the induction of a specific 
level of response; for examples, hypothetically, to induce 50% receptor response 30 µM of ACh 
is required. However, in the presence of the positive allosteric modulator, to induce 50% receptor 
response, only 30 nM of ACh is required (shifting the ACh concentration response curve 
leftward- EC50 is shifted leftward). Therefore, the effect of a leftward shift of the ACh CRC is 
indicative of potentiation of the acetylcholine agonist activity. This further supportss that these 
compounds act allosterically, and that they exert their effects from a binding site that is different 
than that of the acetylcholine binding site. 
 To test for functional selectivity for the M4 mAChR receptor, cells expressing other 
subtypes (M1, M2, M3, and M5) are incubated with the test compound, then an increasing 
concentration of ACh is added. Across all other subtypes, these M4 potentiators fail to initiate 
potentiation effects on the ACh CRC. 
 Structurally, the most active compounds all contain a dimethyl thienopyridine core. It is 
discovered that substitution of these methyl groups with larger groups demolish all functional 
activity.36 Substitution of the primary amine also results in reduction of efficacy. Therefore, 
further chemical derivation occurs at the amide site generating the “VU10000” series. Further in 
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vitro SAR studies of this series utilizing the mentioned assays result in compounds with good 
potentiation of tan EC20 of acetylcholine. Compounds VU10005, VU10008, VU10010 have the 
highest efficacy and potency (Figure 14). VU10010 is the most robust allosteric potentiator; it 
was able to shift the ACh CRC 47-fold to the left and has an rM4 EC50 of 400 nM.36 To confirm 
the selectivity of VU10010 for M4, a selectivity functional assay is performed as mentioned 
earlier using all five mAChR subtypes. It is found to be inactive across all muscarinic receptor 
subtypes, except for M4. 
  
VU10005    VU10008    VU10010 
  
N S HN
O
NH2
CF3
   
EC50: 300 nM   EC50: 715 nM    EC50: 400 nM 
Figure 14. Compounds from optimization effort. 
 
Optimization of VU1001037 
VU10010 suffered from poor physiochemical properties, such as low solubility (log P of 
4.5), and poor pharmacokinetic properties, such as low brain penetration, preventing it from 
being further characterized.37 Low brain penetration could be due to the activity of P-
glycoprotein (P-gp) efflux. P-gp is an efflux transporter on the luminal membrane of epithelial 
cells in the blood-brain barrier.37 It has specificity for a wide range of substrates in order to 
protect the brain from substances that are toxic. This efflux is known to impair the brain 
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penetrability of many drugs. The aminoamide motif (Figure 15) could potentially be a P-gp 
liability. 
 
 
Figure 15. Aminoamide motif: possible P-gp liability. 
 
This susceptibility to P-gp can be reduced by cyclizing the amide and the amine onto the central 
core or introducing a distal fluorine to attenuate the basicity of the amine moiety. To improve 
this pharmacokinetic property, VU10010 has to be chemically optimized. Modifications of the 
central thienopyridine core range from the addition of a CF3 moiety to the core, removal of the 
flanking primary amine, replacing the amine with a methyl group, to completely truncating the 
core by removing all substitutents.37 The SARs are “flat”. In attempts to improve the 
physiochemical properties and solubility of VU10010, alternative amides are explored while 
keeping the central core the same. This derivatization generates a few analogs with interesting 
activity. Within this set of analogs, all aliphatic and non-benzyl amides are inactive at M4. Only 
benzyl, functionalized benzyl, and heteroaryl analogs retained some M4 activity. From this 
library, two compounds (VU0152099 and VU0152100) are discovered to retain M4 activity 
comparable to VU10010 (Figure 16). 
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VU152099    VU0152100 
 
N S HN
O
NH2
O
 
          rM4 EC50: 403 nM    rM4 EC50: 380 nM 
Figure 16. VU0152099 and VU0152100 
 
Both VU0152099 and VU0152100 are confirmed to selectively bind M4 and potentiate 
ACh response from an allosteric site. These compounds are further characterized to show that 
their physiochemical and pharmacokinetic properties are better than those of VU10010. 
Compared to VU10010 with log a P of 4.5, both VU0152099 and VU0152100 have improved 
log P values of 3.65 and 3.6, respectively. They are almost an order of magnitude less lipophilic 
than VU10010. Lower lipophilicity could contribute to their higher solubility property. Because 
they are more soluble, they allow more homogenous dosing for in vivo studies. In vivo brain and 
plasma exposure studies are performed in rats at 56.6 mg/kg administered intraperitoneally. Both 
compounds exhibit high absorption and brain penetration. Therefore, P-gp susceptibility is not a 
major concern for this scaffold. Because both analogs have high brain exposure, they were 
evaluated in a model that is predictive of antipsychotic effect, amphetamine-induced 
hyperlocomotion. Rodent hyperlocomotion is induced with amphetamine, which is a drug that 
mimics hyperlocomotion of the schizophrenic state. VU0152099 and VU0152100 appear to 
reverse the hyperlocomotion activity of amphetamine. Activation or potentiation of the agonist 
response of acetylcholine on M4 muscarinic acetylcholine receptor by these compounds activates  
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NMDA receptors, which increases dopamine turnover, which thereby, reverses amphetamine-
induced hyperlocomotion (Figure 17).37 
 
 
Figure 17. Amphetamine-induced hyperlocomotion is reversed in rats by VU0152099 and VU0152100.37 
 
 
Initial optimization of VU0152099 and VU015210038 
VU0152099 and VU0152100 are efficacious, potent, and selective compounds that 
enhance acetylcholine response via allosteric modulation at the M4 muscarinic receptor with no 
inherent agonistic activity on their own. Their metabolic PK profile is still not ideal for in vivo 
studies. Both analogs have poor metabolic stability leaving only less than 10% of the parent 
compound remaining in human and rat liver microsomes.38 In attempts to search for tool 
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compounds that have improved physiochemical and pharmacokinetic properties, further 
derivitization of VU0152099 and VU0152100 is necessary. Modifications of VU0152100 
include replacing the methyl substituent on the thienopyridine core with various aliphatic, 
aromatics, and functionalized ethers and amines.32 Most modifications result in “flat” SAR with 
no potentiation of the acetylcholine response. The groups that are tolerated generating low 
micromolar potency are analogs containing methylpyridine ethers. Further derivatizations 
involve keeping the Western moiety (ether linkage) constant and varying the amides flanking the 
central core. Out of these analogs, the compound with the best combination of potency and fold 
shift carries a 4-pyridyl ether moiety on the left and a 2,3-difluorobenzyl amide moiety on the 
right with a potency of 2.44 µM and an acetylcholine fold shift of 44 (Figure 18).38 Other 
analogs within this set of compounds also have micromolar potency and fold shifts ranging from 
7 to 67. 
 
Figure 18. Most potent compound from the initial optimization of VU0152100. 
 
 
Further Optimization M4 PAMs 
Out of the initial screen of 232 compounds purchased from ChemBridge, along with hits 
that lead to the generation of VU10010, there was also another hit with micromolar potency. 
Here we utilize diversity-oriented synthesis to explore the structure activity relationship of hit 1 
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(Figure 19) from the ChemBridge screen in addition to continuing the optimization of 
VU0152100. 
 
1 
Figure 19. Another hit from the initial screen of 232 compounds purchased from ChemBridge. 
 
Compound 1 has a potency (EC50) of 4.5 µM in the rat M4/Gqi5 cell line and a potency of 1.7 µM 
in the human M4/Gqi5 cell line. Though these values are within the micromolar range, it can still 
be improved. However, they are a good starting point for SAR studies. We further explore this 
hit by derivatizing both the central core and the amide portion. 
We previously showed that VU0152099 and VU0152100 posses high potency, efficacy, 
and selectivity. However, their in vitro metabolism PK profile indicates that they are heavily 
metabolized after 90 minutes of incubation in rat liver microsomes leaving less than 10% of the 
active parent compound remaining. As a continuing effort to generate compounds that are more 
metabolically stable and posses better pharmacological profile, we further optimize VU0152100 
and its analogs. Two key regions of VU0152100 were derivatized. The new analogs differ from 
those of VU0152100 in the central core and the amide regions. 
 
General chemistry procedure 
Using iterative parallel library synthesis, several sets of compounds are generated from 
the following general amide coupling procedure: amines are coupled to various carboxylic acids 
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using O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), 
N,N-diisopropylethyl amine (DIEA), and either dichloromethane (DCM) or N,N-
dimethylforamide (DMF). Reactions are stirred at room temperature until complete. For those 
carboxylic acids that are not reactive under this amide coupling procedure, they are converted to 
acid chlorides using POCl3 in pyridine at -15 °C. Then they are coupled to their corresponding 
amines (Scheme 1). All compounds are purified to >95% purity using Gilson HPLC or ISCO 
Combiflash Rf systems. Purities are determined with the Agilent liquid chromatography/ mass 
spectroscopy (LCMS) system. Selected compounds were verified using 400MHz Bruker proton 
nuclear magnetic resonance (NMR). 
 
Scheme 1. Amide coupling general schemes. i) HATU, DIEA, DMF, RT overnight, ii) POCl3 pyridine, -15°C until 
completion, then add amine 
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Characterization of allosteric modulators of GPCRsin calcium mobilization assays 
Various assays are used to characterize allosteric modulators. Most functional cell-based 
assays utilize cells that stably express the receptor in question and readouts that are quantifiable 
such a fluorescence of calcium mobilization. The assays used typically are in a ‘double-add’ or 
‘triple-add’ format8. Under a ‘triple add’ format, 10 µM of the test compound is first incubated in 
human M4/Gqi5 cells in the absence of the endogenous ligand (Ach). This incubation establishes a 
baseline to determine whether the compound itself has intrinsic agonist activity.8 If the test 
compound is in fact an agonist, it will potentiate the baseline (Figure 20A).8 Then a submaximal 
concentration of the acetylcholine (EC20) is added. This second add should reveal the ability of 
the compound to amplify agonist activity by the orthosteric ligand. If there is a potentiation of 
activity on top of the submaximal response of the orthosteric ligand, then the compound is 
considered a positive allostertic modulator (PAM) (Figure 20B).8 All potention response is 
compared to the positive control, VU0152100. Next, the third add requires the addition of a 
concentration of the orthosteric ligand that induces a maximal response. If the maximal response 
is not reached, one possibility of this result is an inhibition of agonist activity (Figure 20C).8 
This result is also indicative of no receptor reserve or the receptor is undergoing recovery from 
an earlier agonist or PAM add, therefore, no additional activation can be induced (Figure 20A 
and 20B).8 When the compound is antagonizing the activity of the orthosteric ligand, it is either 
an orthosteric antagonist or a negative allosteric modulator (NAM).8 To determine whether the 
test compound is an orthosteric antagonist or NAM, further characterization is required. 
Competition binding assay can be used to elucidate whether the compound binds orthosterically 
or allosterically. 
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Figure 20. Dotted line displays the action of the endogenous ligand such as acetylcholine for the mAChRs. A) when 
the compound tested acts as an agonist, it displays agonistic activity even before the endogenous ligand is added B)  
when the compound is a potentiator, it is not efficacious on its own, but upon the addition of a submaximal 
concentration of the endogenous agonist, it is able to potentiate activity beyond the efficacy of the agonist C) 
orthosteric antagonist or NAM inhibits response even with the addition of near maximal concentration of agonist.8 
 
Those that show good efficacy from this single point experiment are submitted for further 
in vitro characterization such as its ability to generate a concentration response curve (CRC). The 
concentration response curve of each compound is generated by incubating increasing 
concentration of the test compound in cells then adding a submaximal concentration of 
acetylcholine. The CRC curve determines the effective concentration of the compound required 
to generate 50% response (EC50) (Figure 21). 
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Figure 21. Concentration response curve (CRC). 
 
The allosteric potentiation ability of the test compound is further tested in ACh CRC 
fold-shift assay (Figure 22). Cells are incubated with a fix concentration of the test compound 
that would generate a maximal response. Then an increasing concentration of ACh is added. A 
leftward shift of the ACh CRC is indicative of robust potentiation of the agonistic effect of ACh 
on the M4 receptor.36  
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Figure 21. Fold shift of ACh CRC by test compound. 
 
To test for selectivity for the M4 muscarinic acetylcholine subtype, the same single point 
Ca2+ mobilization assay is run using other mAChR subtypes. Then this selectivity is confirmed 
by generating a concentration response curve of the test compound using the corresponding 
subtypes. Compounds that are selective for the M4 receptor should not have activity across the 
other subtypes. 
Compounds that have high efficacy, potency, and selectivity against other muscarinic 
subtypes are further characterized for their pharmacokinetic (PK) properties. For those selected 
compounds that display good PK profiles, they are further tested in animal models of 
antipsychotic behavior.  
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Optimization of HTS hit 1 
Using diversity-oriented synthesis, we generate a set of compounds with a wide range of 
amides in an attempt to probe for functional groups that yield better efficacy and potency 
compared to the hit compound 1. This library is synthesized using the amide coupling procedure 
described above. The carboxylic acids used ranges from aliphatic groups to aromatics and 
heterocyclic groups. The results from this set of compounds ranges from no potentiation to 
robust potentiation at the human M4 receptor. Compounds that potentiate the activity of the 
submaximal concentration of acetylcholine (EC20) have response higher than the response 
generated by the EC20 (Figure 22).  
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Figure 22. Single point data of methoxy benzothiazole analogs at the human M4 receptor. 
 
We resynthesize the original hit to reconfirm its activity. The resynthesized hit compound 
1 (VU0236776) has an ECmax of 61.23 and potency of 1.86 µM, which reconfirms the original 
data. Results show that a few compounds do in fact potentiate the EC20 of acetylcholine. To 
further investigate the effect of the dihydrodioxine amide from 1 on potency, we investigate 
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similar ring systems such as tetrahydropyran, methylated dihydrodioxine, and 
benzodihydrodioxine (Figure 23). Compared to the lead compound, 2-amide tetrahydropyran 
(VU0415147-1) and 3-amide tetrahydropyran (VU0415152-1) congeners are less efficacious and 
less potent. They have ECmax of 66.24, 35.40 and potencies of 3.6 µM and 9.5 µM, respectively. 
When dihydrodioxine is methylate (VU0415155-1), activity is completely abolished. 
Structure VU Number ECmax EC50 (nM) 
 
VU0415147-1 66.24 3640 
 
VU0415152-1 35.40 9530 
 
VU0236776-4 61.23 1890 
 
VU0415155-1 20.04 inactive 
 
VU0415146-1 20.62 inactive 
 
Figure 23. Analogs of 1 with similar ring systems. 
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Among the aliphatic groups used, it is observed that as the chain size increases, efficacy 
and potency increase (Figure 24). Foramide (VU0419303-1) is inactive compared to acetamide 
(VU0409528-1), which has a potency of >10 µM, and butyramide (VU0409083-1), which has an 
EC50 of 6.1 µM. As these chains become branched, activity is abolished as seen in the t-butyl 
analog (VU0409094-1). With the addition of an oxygen onto the butyramide chain (VU0409096-
1), potency remains around 6.5 µM. 
 
Structure VU Number ECmax EC50 (nM) 
 
VU0419303-1 16.87 inactive 
 
VU0409528-1 28.44 >10000 
 
VU0409083-1 71.84 6050 
 
VU0409522-1 39.58 >10000 
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VU0409094-1 21.48 inactive 
 
VU0409096-1 65.79 6540 
 
VU0415149-1 16.70 inactive 
 
VU0415150-1 17.79 inactive 
 
Figure 24. Aliphatic analogs of 1. 
 
As for the cyclized aliphatic groups, there is no clear trend with increasing ring size 
(Figure 25). Cyclopropane (VU0409095-1) and cyclobutane (VU0419302-1) have potencies that 
are comparable to each other (EC50 of 4.6 µM and 3.4 µM). Both cyclopentane (VU0409526-1) 
and cyclohexane (VU0409088-1) have potencies greater than 10 µM. Among the cyclopropane 
analogs, potency is completely abolished when a methyl spacer (VU0419301-1) is introduced 
between the cyclopropane ring and the amide. With the addition of a methyl group to the 
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cyclopropane ring (VU0415153-1), potency decreases to an EC50 of 5.3 µM, and no activity is 
detected when a longer chain is tethered to cyclopropane (VU0415154-1).  
 
Structure VU Number ECmax EC50 (nM) 
 
VU0409095-1 79.55 4600 
 
VU0419301-1 11.05 inactive 
 
VU0415153-1 65.85 5280 
S
N
NH
O
O
 
VU0415154-1 16.70 inactive 
 
VU0419302-1 47.17 3410 
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VU0409526-1 47.53 >10000 
 
VU0409088-1 50.73 >10000 
 
Figure 25. Cyclized aliphatic analogs of 1.  
 
It appears that the most efficacious compound among this series with the highest ECmax 
(100.27) contains a 4-pyridyl amide (VU0409524-1). Its counterparts are less potent in 
comparison; 2-pyridyl amide (VU0415148-1) has an ECmax of 25.22, and 3-pyridyl amide 
(VU0409524-1) has an ECmax of 39.62 (Figure 26). The 4-position seems to yield the highest 
efficacy. Their potencies do not clearly distinguish a major difference between the 3 and 4 
position of the substitution, but a 10-fold difference can be seen in comparison to the 2-position. 
The 4-pyridyl substituted analog has an EC50 of 1.1 µM while the 3-pyridyl analog has an EC50 
of 2.5 µM, and the 2-pyridyl analog has potency greater than 10 µM. In comparison to the 3-
pyridyl moiety, the addition of a nitrogen onto the 3-pyridyl ring (VU041515-1) decreases 
acetylcholine max response. However, this pyrazine analog appears to be the most potent 
compound of this set with an EC50 of 744 nM. Though this pyrazine analog has nanomolar 
potency, its low efficacy prevents it from being a useful compound. 
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Structure VU Number ECmax EC50 (nM) 
 
VU0415148-1 25.22 >10000 
 
VU0409523-1 39.62 2480 
 
VU0409524-1 100.27 1120 
 
VU0415151-1 33.90 744 
 
Figure 26. Pyridine analogs of 1. 
 
All other analogs of this series are inactive, with the exception of 4-fluorobenzamide 
(VU0409084-1), which has a potency of 3.5 µM, and furan (VU0409087-1), which has a potency 
of 1.6 µM (Figure 27). In terms of efficacy, the furan analog is the most efficacious among the 
remaining analogs with an ECmax of 58.85. The subtle trend of increasing efficacy as the 
substitution position changes can be seen in both fluoro-substituted and cyano-substituted rings. 
However, because potentiation by these analogs is so low, they are deemed inactive. 
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Structure VU Number ECmax EC50 (nM) 
 
VU0409092-1 26.10 inactive 
 
VU0409521-1 22.46 inactive 
 
VU0409085-1 21.56 inactive 
 
VU0409090-1 22.58 inactive 
 
VU0409084-1 25.44 3540 
 
VU0409525-1 16.45 inactive 
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VU0409531-1 18.25 inactive 
 
VU0409532-1 19.62 inactive 
 
VU0409529-1 18.90 inactive 
 
VU0409527-1 18.40 inactive 
 
VU0409097-1 20.96 inactive 
 
VU0409530-1 29.43 inactive 
 
VU0409089-1 20.35 inactive 
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VU0409086-1 44.50 inactive 
 
VU0409087-1 58.85 1620 
 
VU0409093-1 22.81 inactive 
 
VU0409091-1 16.07 inactive 
 
Figure 27. Additional analogs of 1. 
 
Compounds among this methoxy methyl benzothiazole series do not appear to have 
significantly better potency in comparison to 1. It is observed that pyridines are better tolerated. 
Structure activity relationship between aliphatics, aromatic, and functionalized aromatic analogs 
within this subset of compounds indicate a possible discrimination against ring size and position 
of functionalization. 
To further derivatize 1, the methoxy methyl benzothiazole core is replaced with 
benzothiazole (Figure 28). This truncation of the central core is an experiment to test whether 
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efficacy and potency are driven from substitution of the central core. The same amide coupling 
protocol described earlier is used to generate this set of compounds. No active compounds are 
observed. Some of the same side chains that display efficacy and potency from the previous set 
of analogs do not produce similar profile with this core substitution. From the previous set of 
analogs, it is observed that the 4-pyridyl substituent (VU0409524-1) has good efficacy and low 
micromolar potency. When the methoxy and methyl substituents are removed from the central 
core, activity is abolished.  No potentiation is seen among analogs that were active in the 
previous series. This benzothiazole core produces no active PAMs. 
Structure VU Number ECmax EC50 (nM) 
 
VU0166610-4 20.31 inactive 
 
VU0419287-1 20.20 inactive 
 
VU0155360-3 16.75 inactive 
 
VU0419283-1 16.44 inactive 
 
VU0419284-1 15.70 inactive 
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VU0419285-1 15.19 inactive 
 
VU0419286-1 18.30 inactive 
 
VU0419288-1 18.43 inactive 
 
VU0419291-1 16.01 inactive 
 
VU0419290-1 16.18 inactive 
 
VU0419282-1 19.81 inactive 
 
VU0419289-1 17.71 inactive 
 
VU0195412-5 12.73 inactive 
 
VU0419292-1 15.23 inactive 
 
Figure 28. Analogs of truncated central core (benzothiazole). 
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To examine whether the introduction of a heteroatom within the central core has any 
affect on efficacy and potency, we replace the truncated benzothiazole core with thiazolopyridine 
(Figure 29). Using some of the same congeners that previously showed activity in the methoxy 
methyl benzothiazole series, we generate a library using thiazolopyridine. Similarly to 
benzothiazole, this thiazolopyridine core produces only inactive compounds. 
 
Structure VU Number ECmax EC50 (nM) 
 
VU0419293-1 13.80 inactive 
 
VU0419294-1 18.98 inactive 
 
VU0419297-1 15.77 inactive 
 
VU0419296-1 16.18 inactive 
 
VU0419295-1 16.11 inactive 
 
VU0419298-1 16.35 inactive 
 
Figure 29. Replacing the methoxy methyl benzothiazole core. Analogs of thiazolopyridine core. 
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To further examine the effect of altering the central core on efficacy and potency, we 
replace the methoxy methyl benzothiazole core with hydroxymethyl benzothiazole (Figure 30). 
The congener of choice for this set is cyclopropane, which has good efficacy of 79.55 and a 
potency of 4.6 µM. As seen here, replacing the methoxy substituent of the central core with 
hydroxy does not have dramatic effects on the efficacy and potency of these analogs. 
 
 
  
 
VU0409095-1 
ECmax: 79.55 
EC50: 6.00 µM 
VU0415153-1 
ECmax: 65.85 
EC50: 5.28 µM 
 
VU0419299-1 
ECmax: 43.80 
EC50: 5.16 µM 
VU0419300-1 
ECmax: 44.74 
EC50: 4.97 µM 
 
Figure 30. Result of replacing the methoxy substituent on the central core with hydroxy in comparison to the 
analogs carrying the original central core. 
 
 Among the analogs generated, those with high potency and efficacy are selected for further 
characterization. The effect of a maximal concentration of these compounds on the ACh CRC is 
determined (ACh fold-shift assay). VU0409524-2, VU0409095-1, and VU0409523-1 are 
selected for further analysis (Figure 31). The methoxy methyl benzothiazole analog that carries 
the 4-pyridine eastern moiety (VU0409524-2) has the highest fold shift of 15. Out of the three 
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compounds tested, it is observed that VU0409524-1 has the highest potentiation amd it shifts the 
ACh CRC leftward the farthest. The analog carrying the cyclopropyl moiety (VU0409095-1) is 
able to shift the ACh CRC leftward by 4.9 fold, and the 3-pyridyl moiety (VU0409523) is able to 
shift the ACh CRC leftward by 2.7 fold. 
 
 
 
 
 
 
 
 
 
 
      
       VU0409524-2                    VU0409095-1             VU0409523-1    
        EC50: 1.12 µM                      EC50: 4.6 µM              EC50: 2.48 µM 
 
Figure 31. Fold shift result of most efficacious and potent analogs of 1. 
 
In conclusion, attempts to improve efficacy and potency of 1 result in analogs with 
potencies within the low micromolar range that are comparable to 1. It is observed that the 
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methoxy methyl substituents on the central core are important for activity. Truncating the central 
core, by removing these substituents, results in analogs with no activity. A subtle trend among 
the pyridine congeners is detected. The position of the nitrogen affects activity. The 4-pyridyl 
analog is most potent in comparison to the 2- and 3-pyridyl analogs. 
 
Optimization of VU0152100 
 
As mentioned earlier, even though VU0152099 and VU0152100 have good efficacy, 
potency, and selectivity, their metabolic PK profile is still not ideal. They are metabolized in 
human and rat liver microsomes leaving less than 10% of the parent compound remaining. 
Paralleling the optimization effort of VU0152100 mentioned earlier, in an attempt to optimize 
VU0152100, the central core and the amide linker are modified. For comparison, some of the 
same amines previously used to generate VU0152100 and their analogs are utilized. Kennedy P., 
et al. shows that some of the amides that are tolerated in the analogs that they generated range 
from aliphatic groups such as t-butyl to di-fluorinated aromatic groups.38 
We first observe the effect of modifying the central core. A set of analogs are generated 
using bromocyclopropyl thienopyridine (Figure 32). It is seen that among all the congeners 
synthesized, the most efficacious analog contains a cyclopropane ring (VU0448244-1). It has an 
ECmax of 59 and a potency of 1.6 µM. This set of analogs produce “flat” SAR; all other analogs 
are inactive. 
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Structure VU Number ECmax EC50 (nM) 
 
VU0448215-1 17 inactive 
 
VU0448181-1 29 inactive 
 
VU0448244-1 59 1630 
 
VU0448120-1 24 inactive 
 
VU0448145-1 25 inactive 
 
VU0448146-1 27 inactive 
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VU0448162-1 31 inactive 
 
VU0448177-1 28 inactive 
N S HN
NH2
Br O
 
VU0448188-1 26 inactive 
 
VU0448247-1 24 inactive 
 
VU0448230-1 27 inactive 
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VU0448196-1 23 inactive 
 
Figure 32. Results of replacing the central core of VU0152100. All analogs are inactive, except for the analog 
carrying cyclopropylamide. 
 
To further modify the central core of VU0152100, we substitute the dimethyl 
thienopyridine core with chlorodimethyl thienopyridine. Then we proceed with amide coupling 
with various amines ranging from aliphatics to aromatics and functionalized aromatics.  
 
Synthesis of 3-amino-5-chloro-4,6-dimethylthieno[2,3-b]pyridine-2-carboxylic acid 
N
Cl
S
NH2
O
OHN
Cl
Cl
N
HS
O
O
NaOH/MeOH
 
To a 20 mL microwave vial fitted with a magnetic stir bar, 2,5-dichloro-4,6-
dimethylnicotinonitrile (1 g, 5.0 mmol) and MeOH (10 mL) are added. Methyl thioglycolate 
(490 µL, 5.5 mmol) is added followed by the addition of a 1 M solution of NaOH (aq, 10 mL, 25 
mmol). The microwave vial is sealed and the solution is heated to 125 °C for 30 min.  The 
reaction is cooled to room temperature and a solution of HCl is added until the solution reaches 
the pH of 1. The precipitate that formed is filtered and dried in a vacuum oven at 50 °C for 24 h. 
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The solids are of sufficient purity to use without further purification.  1H NMR (400 MHz, d6-
DMSO, δ (ppm)): 6.833 (s; 2H), 2.84 (s; 3H), 2.63 (s; 3H).   
Synthesis of 3-amino-N-(benzo[d][1,3]dioxol-5-ylmethyl)-5-chloro-4,6-dimethylthieno[2,3-
b]pyridine-2-carboxamide 
N
Cl
S
NH2
O
OH N
Cl
S
NH2
O
HN
H2N
HATU, DIEA, DMF
O
O
O
O
 
To a 20 mL vial fitted with a stir bar and a setum cap, 3-amino-5-chloro-4,6-dimethylthieno[2,3-
b]pyridine-2-carboxylic acid (125 mg, 0.50 mmol) and and DMF (3 mL) are added. Then 
piperonylamine (90.9 µL, 0.75 mmol) is added followed by diisopropylethylamine (499 µL, 1.0 
mmol) and 2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate 
methanaminium (HATU, 190 mg, 0.50 mmol). The solution is stirred at ambient temperature 
overnight. Then it was concentrated and purified via Gilson HPLC purification system. 1H  NMR 
(400 MHz, d6-DMSO, δ (ppm)): 8.3 (t; J = 6.0 Hz; 1H), 6.9 (broad s; 2H), 6.8 (d; J = 8.0 Hz; 
1H), 6.75 (dd, J = 8.0 Hz; 1H), 5.9 (s; 2H), 6.9 (bs; 2H), 4.3 (d; J = 6.0 Hz; 2H), 2.8 (s; 3H), 2.6 
(s; 3H).  
Synthesis of all other analogs follows this procedure. 
The SAR of these analogs produces a number of compounds with robust potentiation. 
The potencies of these compounds range from greater than 10 µM down to 10 nM. Of the 
aliphatic amides used, there is no clear trend between chain/branched versus cyclized analogs. 
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The potencies of some analogs from this series are better in comparison to the potencies of 
VU0152099 (EC50 403 nM) and VU0152100 (EC50 380 nM) such as potencies of the following 
aliphatic compounds (Figure 33). The most notable compound is VU0449033-1 carrying 
cyclopropyl amide, which has a high potency of 19.4 nM. In comparison, potency decreases 10-
fold (188 nM) as the ring size increases to cyclohexyl amide (VU0452029); potency decreases 
even further by 100-fold (1.1 µM) when a methyl spacer is added between the amide and the 
cyclohexyl ring (VU0452142). In general, these analogs generate submicro molar potencies that 
are better than VU0152099 and VU015210. 
Structure VU Number ECmax EC50 (nM) 
 
VU0448053-1 89 337 
 
VU0448042-1 90 293 
 
VU0449064-1 ---- 183 
 
VU0449033-1 ---- 19.4 
N S HN
NH2
Cl O
 
VU0452029-1 ---- 188 
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VU0452142-1 ---- 1090 
 
Figure 33. Aliphatic analog results of replacing the central core of VU0152100. 
 
In comparison to the cyclohexyl amide analog, the introduction of an oxygen into the 
cyclohexyl ring (tetrahydropyran analog VU0452127-1) does not dramatically change the 
potency. Its EC50 of 220 nM remains near that of the cyclohexane moiety. In comparison to the 
tetrahydropyran analog, oxetane (VU0459382-1) has a lower potency of 906 nM. With an EC50 
of 28.7 nM, tetrahydrofuran (VU0459381-1) is the most potent analog of these oxygen 
containing aliphatic rings. It is 10-fold more potent than the tetrahydropyran analog and is 30 
fold more potent compared to oxetane. No clear trend is detected among these analogs, however 
tetrahydrofuran has a notable potency (Figure 34). 
 
Structure VU Number ECmax EC50 (nM) 
 
VU0459382-1 ---- 906 
 
VU0459381-1 ---- 28.7 
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VU0452127-1 ---- 220 
 
Figure 34. results of oxygen containing cyclized aliphatic analogs. 
 
In comparison to VU0152099 and VU0152100, analogs of this series are more potent 
(Figure 35). Replacing the central core of VU0152099 increases potency 7-fold from 403 nM to 
56.9 nM. Potency of VU0152100 increases about 3-fold from 380 nM to 117 nM. 
 
 
 
 
 
VU0152099 
EC50: 403 nM 
VU0152100 
EC50: 380 nM 
 
VU0448057-1 
EC50: 56.9 
VU0448098-1 
EC50: 117 
 
Figure 35. Comparing VU0152099 and VU0152100 to their analogs in the chlorodimethyl thienopyridine series. 
 
Similarly to the pyridyl analogs of 1 mentioned above, pyridine analogs within this series 
also display similar trend of nitrogen position-dependent activity. Potency is affected by the 
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position of the nitrogen on the pyridine ring (Figure 36). 2-pyridine (VU0452032-1) has a 
potency of 293 nM, while 3-pyridine (VU0452129-1) is more potent with an EC50 of 94.9 nM, 
and 4-pyridine (VU0448088-1) is the most potent with EC50 of 40.0 nM. As a result of this 
robust potentiation among the pyridyl analogs, additional pyridyl analogs are generated. 
Similarly to the pyridyl analogs, this trend of nitrogen position-dependent potency is also 
observed among analogs containing a methylated methyl spacer. When the nitrogen is in the 2-
position (VU045367-18) the EC50 is 1.41 µM; when the nitrogen is in the 3-position 
(VU0453649-1), potency increases an additional 10-fold to an EC50 of 601 nM; when the 
nitrogen is moved to the 4-position (VU0453628-1), the potency remains near that of the 3-
position displaying an EC50 of 600 nM. Potency decreases when the methyl spacer is 
homologated. Compared to the 2-methylpyridine analog (VU0452032-1), which has a potency of 
293 nM, the 2-ethylpyridine analog (VU0459327-1) is slightly less potent producing an EC50 of 
686 nM. The 3-ethylpyridine moiety (VU0459383-1) is unable to potentiate acetylcholine 
agonist activity, while the 3-methylpyridine (VU0452129-1) moiety has a potency of 94.9 nM. 
When the nitrogen is moved to the 4-position (4-ethypyridine VU0456952-1), activity is 
regained producing an EC50 of 121 nM, which is 10-fold less than that of 4-methylpyridine 
(VU0448088-1).  In general, among these pyridine analogs, the 4-position is more preferable. 
The length of the spacer is important to potency. It is observed that the shorter spacer generates 
better potency. 
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Structure VU Number ECmax EC50 (nM) 
 
VU0452032-1 ---- 293 
 
VU0452129-1 ---- 94.9 
 
VU0448088-1 93 40.0 
 
VU0453678-1 ---- 1410 
 
VU0453649-1 ---- 601 
 
VU0453628-1 ---- 600 
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VU0459327-1 ---- 686 
 
VU0459383-1 ---- inactive 
 
VU0456952-1 ---- 121 
 
Figure 36. Results of pyridine analogs. 
 
Next, we observe the effect of adding an additional nitrogen to the pyridine ring (Figure 
37). Data from the pyridine analogs above establish that potency increases as nitrogen is moved 
from 2- to 3- to 4-position. Of the di-nitrogen containing rings, this trend can subtly be seen. The 
potency displays by each nitrogen in these analogs is additive; the final potency of each analog is 
the summation of the potency of each nitrogen on the ring. For example from the above data, 2-
pyridine displays the lowest potency (293 nM). Hence, when when the nitrogens are in the 2- and 
6-position (VU0456925-1), potency is even lower (EC50 1.07 µM). Having a nitrogen in the 6-
position is similar to having a nitrogen in the 2-position if atom count starts on the side 
containing the 6-nitrogen (like having nitrogen in two 2-positions). When the 2-position nitrogen 
is held constant and the other nitrogen is walked around the ring, potencies are still lower than 
those of pyridines above (additive effect). However, it can still be observed that walking the 
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second nitrogen from 2- to 3- to 4-postion increases potency within this series. VU0459384-1 
has nitrogens at the 3- and 4-position, which are the more potent positions; therefore, its potency 
of 222 nM is better than the other analogs in the same series. 
 
Structure VU Number ECmax EC50 (nM) 
 
VU0456925-1 ---- 1070 
 
VU0452102-1 ---- 262 
 
VU0456953-1 ---- 243 
 
VU0459384-1 ---- 222 
 
Figure 37. Results of dinitrogen-containing analogs. 
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 Next, the chlorodimethyl thienopyridine core is replaced with hydroxydimethyl 
thienopyridine (Figure 38). It is observed that replacement of the chlorine with hydroxyl 
abolishes activity shown with VY0458326. Potency of the benzyl analog decreases from 90.8 
nM to greater than10 µM. 
 
 
 
VU0458326  
EC
50
 > 10 µM
 
 
 
VU0448087 
EC
50 
= 90.8 nM  
  
Figure 38. Replacing the chlorodimethyl thienopyridine with hydroxydimethyl thienopyridine. 
  
 To conclude, there is a strong correlation between the position of the nitrogens on the 
benzene ring and potency. As nitrogen is moved from 2- to 3- to 4-position, potency increases. It 
is observed that the 4-postion is better tolerated. Also, it is observed that some analogs of the 
chlorodimethyl thienopyridine core are more potent than VU0152100. This chlorodimethyl 
thienopyridine core is essential for activity. Replacing it with bromocyclopropyl thienopyridine 
or hydroxydimethyl thienopyridine yields inactive compounds or compounds with low potencies. 
 
Fold shift 
 We further characterize a selected set of compounds that have good efficacy and potency to 
establish their ability to shift the acetylcholine concentration response curve. There is also a  
N S
NH2
O
HN
HO
N S
Cl
NH2
O
HN
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subtle trend accompanying the fold shift data (Figure 39). As we have observed before, 
potencies of analogs containing the pyridyl moiety is dependent on the position of the nitrogen. 
This can also be seen in the ACh CRC fold-shift ability. In the absence of nitrogen in the phenyl 
ring (VU0448087-1), the fold shift is 38. In the presence of a nitrogen (pyridyl moieties), fold 
shift increases dependent on the position of the nitrogen. The 4-methylpyridine analog 
(VU0448088-1) has a fold shift of 139, while its counterpart, 3-methylpyridine (VU0452129-1), 
has a much lower fold shift of 55. Fold shift increases dramatically as the nitrogen migrates from 
the 3- to 4-position.  
 As mentioned earlier, it is observed that potency of those analogs carrying pyridine 
congeners decreases with increasing spacer length. This decrease in potency also translates to 
fold shift. In comparison to VU0448088-4 (fold shift 139), which has a spacer that is one carbon 
long, the 4-ethylpyridine moiety (VU0456952-1), containing a homologated spacer, has a much 
smaller fold shift of 91. The potency additive theory mentioned earlier involving the addition of 
a second nitrogen to the 2-pyridine ring is observed with VU0456953-1 and VU0448088-4. 
VU0456953-1, which contains nitrogens in the 2- and 4-position, has a fold shift that is lower 
than VU0448088 (139 versus 62), which contains a nitrogen in the 4-position, because it also 
contains a nitrogen in the less potent position. Another important analog with a significant fold 
shift carries a cyclopropane ring (VU0449033-1). It has the largest ACh CRC fold shift of 380. 
Some analogs if this series appears to have better fold shifts in comparison to VU0152100 (fold 
shift 27). See Appendix for ACh CRC fold shift curves. 
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VU0448087-1 
EC50 = 90.8 nM  
Fold shift = 38 
 
VU0452129-1 
EC50 = 94.9 nM  
Fold shift = 55 
 
VU0448088-4 
EC50 = 40 nM  
Fold shift = 139 
 
VU0456952-1 
EC50 = 121 nM  
Fold shift = 62 
 
VU0456953-1 
EC50 =  243 nM  
Fold shift = 62 
 
VU0449033-1 
EC50 =  19.4 nM  
Fold shift = 380 
 
Figure 39. Some subtle fold shift trends. 
N
N
N
N
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Selectivity 
 To further characterize compounds with good potency and fold shift, selectivity of these 
analogs for the M4 muscarinic acetylcholine receptor is evaluated. This selectivity screen is 
performed in both human M4/Gqi5 and rat M4/Gqi5 cells. As mentioned earlier, to test for 
selectivity for the M4 mAChR receptor, single point Ca2+ mobilization functional assay and 
concentration response curve of the test compound has to be generated in cells expressing the 
other subtypes (M1, M2, M3, and M5). These M4 potentiators ideally fail to potentiate 
acetylcholine response across all other subtypes, except for M4.36 Here, only a few example data 
sets are shown. Data for the remaining compounds can be viewed in the Appendix. VU0449033 
has the largest fold shift of 380 and an EC50 of 19.4 nM. In human cells, it is active at hM4, hM1, 
and hM2 muscarinic receptors (Figure 40). It has efficacy and potency in all three receptors, but 
the highest effect is in M4. Its potency in M4 is 35.5 nM, while in M1 and M2 are 969 nM and 548 
nM, respectively. VU0449033 is not completely selective for the human M4 mAChR. Similarly 
in rat, it shows potentiation in rM4, rM1, and rM2 (Figure 41).  
 Another analog submitted to selectivity screening is VU0448088, which is shown to be 
selective for both human and rat M4/Gqi5 (Figure 42 and 43). Its potency (EC50) of 83.3 nM is 
reconfirmed in the human cell line. In rM4, it is slightly less potent generating an EC50 of 173.3 
nM. There’s a 10-fold difference in potency between the human and rat cell line. All other 
analogs from the fold shift experiment above (VU0452129, VU0448099, VU0452055, 
VU0452127, VU0456952, VU0456953) are selective for the M4 subtype (see Appendix). 
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VU0449033 
 
 
Figure 40. Human cell line selectivity data across all subtypes. 
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VU0449033 
 
 
Figure 41. Rat cell line selectivity data across all subtypes. 
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VU0448088 
 
 
Figure 42. Human cell line selectivity data across all subtypes. 
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VU0448088 
 
 
 
Figure 43. Rat cell line selectivity data across all subtypes. 
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Pharmacokinetic (Figure 44)  
 A few selected analogs are chosen for further pharmacokinetic evaluation. Some of the 
important properties to consider are solubility, clearance, fraction of free drug available for 
action, and metabolism. The ability of a compound to be absorbed is partially dependent on its 
ability to be solubilized for dosing, which is partially determined by its lipophillicity. High 
lipophillicity, or high cLogP, could is predictive of low solubility. Low solubility interferes with 
absorption into cells. cLogP values of greater than 5 is typically associated with low 
absorption39. We previously showed that VU10010 has low solubility, has a cLogP of 4.5, and 
has low brain penetration. VU0152099 and VU0152100 both have cLogP values lower than 
VU10010 (3.65 and 3.6, respectively).37 They both are more soluble, and they both display better 
brain penetration. Some analogs of this chlorodimethyl thienopyridine series have better cLogP 
values. Since lower cLogP values could potentially contribute to better solubility, more 
homogenous dosing would be possible. 
 Another parameter to consider is clearance. Intrinsic clearance is the ability of the liver to 
remove or metabolize drugs. It measures the activity of drug metabolizing enzymes in the liver. 
High clearance indicates that the drug is being highly metabolized or cleared. The data below 
shows that VU0449033 carrying the cyclopropyl congener and VU0456925 have the lowest 
clearance40, 41. 
 Next, we examine the protein plasma binding of these compounds. The extent to which a 
drug is bound to plasma protein is expressed as fraction unbound (fu). Fraction unbound is 
dependent on the binding affinity of the drug and the protein, the concentration of drug available, 
and the concentration of protein available40. The higher the fraction of drug is unbound to plasma 
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protein, the higher the concentration of drug is likely available for action. Both VU0449033 and 
VU0448088 display the highest fraction of unbound drug.  
 Cytochrome P450 is a family of enzymes responsible for most drug metabolism due to 
their ability to bind many substrates. Metabolism can range from the catabolism of the 
compound to deactivation of the compound therefore attenuating its biological activity and 
accelerating its clearance42. Compounds that have no activity at these enzymes have a better 
chance of getting to the target site. It appears that all the analogs tested display low micromolar 
inhibition of CYP450 1A2. VU0449033, and VU0456925 are inactive at all the other CYP45 
subtypes with potency greater than 10 µM. 
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Figure 44. Pharmacokinetics data. Data table is adopted from Corey Hopkin 
 
VU0448088  VU0452129  VU0449033 VU0448057 VU0448087 VU0456925 
 
 
 
 
 
 
 
M4 EC50 ( nM) 34 95 31 48 73 1070 
MW  346.83 346.83 295.79 389.86 345.85 347.82 
cLogP  TPSA  2.19  80.9  2.19  80.9  2.25  68.0  3.20  86.5  3.44  68.0  1.23  93.8  
In Vitro Clearance (mL/min/kg)  
hCLINT  183.4 261 41.1 577 452 32.7 
rCLINT  261.0 275 188 397 626 Stable* 
PPB (% fu) 
rPPB (% fu)  1.7 3.4 6.4 0.1 0.2 4.4 
hPPB (% fu)  2.6 0.9 1.1 0.1 0.2 2.5 
CYP450 (mM)  
1A2  0.12 0.18 <0.1 1.30 0.17 1.2 
2C9  <0.1 4.32 >10 6.42 2.08 >30 
2D6  0.70 >30 >30 24.71 8.66 >30 
3A4  2.75 3.46 >30 6.87 >30 >30 
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Behavioral characterization 
 VU0448088 is selected for further characterization in an animal behavioral paradigm that is 
indicative of antipsychotic effects. Its ability to inhibit amphetamine induced hyperlocomotion is 
observed with dosing of the compound from 3mg/kg up to 100mg/kg. Amphetamine is a drug 
that mimics hyperlocomotion of the schizophrenic state. Compounds that have antipsychotic-like 
effects will be able to reverse amphetamine induced hyperlocomotion. At higher concentration, 
VU0448088 appears to exhibit some reversal of hyperlocomotion effects immediately after 
administration (Figure 45). It slightly inhibits the action of amphetamine on locomotion 
(decrease in mean breaks). However, the effect is short acting. After exerting some modest 
reversal in hyperlocomotion activity for 40 seconds, hyperlocomotion is reverted back to the 
same level as amphetamine. This short acting effect is seen at low concentrations of VU0448088 
(3mg/kg, 10mg/kg, and 30mg/kg). At 100mg/kg, the reversal effect seems to last about 60 
seconds. VU0448088 does not completely reverse amphetamine induced hyperlocomotion; its 
efficacy is slight and short acting. 
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Figure 45. Amphetamine-induced hyperlocomotion data ov VU0448088. 
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Chapter III 
 
SUMMARY 
 
 Schizophrenia is a complex neurological disorder that is represented by a large spectrum of 
symptoms. These symptoms can fall into 3 categories: positive, negative, and cognitive. Positive 
symptoms include hallucinations, delusions, disorganized thinking, and hearing of voices. 
Negative symptoms include social withdrawal, and cognitive symptoms include memory loss, 
lack of attention, and being unable to process information. Current antipsychotics provide 
symptomatic relief for psychoses; however, their effectiveness is variable and side effects are 
occassionally greater than their benefits. 
 The current atypical antipsychotics are successful at treating positive symptoms; however, 
they have little efficacy on negative and cognitive symptoms. Most atypical antipsychotics are 
GPCR antagonists which inhibit dopamine and serotonin receptors. However, due to their lack of 
selectivity numerous undesirable side effects are associated with these treatments. Therefore, this 
leads to the search for a new mode of pharmacology in an attempt to reduce side effects and 
better control symptoms. 
 Studies using muscarinic receptor knockout mice implicate M1 and M4 in the 
pathophysiology of schizophrenia. Muscarinic receptors are mechanistically linked to 
schizophrenia and cognitive deficits. Pharmacologically, non-selective muscarinic antagonists 
exacerbate, whereas agonists ameliorate, cognitive deficits and psychotic behaviors in animal 
models and patients suffering from Alzheimer’s disease and schizophrenia. 
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 Xanomeline, an M1/ M4 preferring partial agonist is efficacious in animal models predictive 
of antipsychotic behaviors. In clinical trials, it reduces psychotic behaviors and improves 
cognitive deficit in Alzheimer’s patients. In a small schizophrenia trial, it improves positive, 
negative, and cognitive symptoms. Due to lack of subtype selectivity, xanomeline exhibits 
intolerable side effects rendering it an unsuccessful clinical candidate. 
 The current thought of the etiology of schizophrenia is one of an imbalanced dopaminergic 
system. M4 muscarinic acetylcholine receptors are highly expressed in dopamine rich regions of 
the brain. In knockout mice studies, M4 is implicated in the regulation dopaminergic neurons 
involved in movement and cognition. Therefore, M4 mAChR emerges as the key regulator of 
dopaminergic hyperactivity. Selective M4 activator may be a useful antipsychotic agent. 
However, no selective small molecule tools exist to provide pharmacological validation of the 
M4 subtype being involved in pathways relating to schizophrenia. Attempts to develop selective 
M4 compounds have been unsuccessful at the orthosteric binding site, site which the endogenous 
agonist, acetylcholine, binds. This is due to the high structural homology across the five 
muscarinic subtypes. Muscarinic receptors also display allosteric binding sites that have greater 
sequence divergence across the five subtypes and, hence, provide an alternative means of 
attaining selectivity. 
 The recent discovery of LY2033298 by Chan and coworkers spur further research into the 
field (Figure 46). LY2033298 is a positive allosteric modulator discovered to have high potency 
and selectivity at the M4 muscarinic acetylcholine receptor. However, it is not an ideal tool 
compound because it has to be co-dosed with oxotremorine in vivo (5). Because oxotremorine is 
a non-selective agonist, data obtained from this co-dosing will be the results of the action of both 
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LY2033298 and oxotremorine. Therefore, no definitive conclusion can be made about the action 
of LY2033298 alone. 
 
  
LY2033298 
Figure 46. Structure of LY2033298. 
 
 Over the years our lab, in collaborations with Dr. Jeff Conn’s lab, has developed several 
M4 PAMs (VU10010, VU0152099, VU0152100) (Figure 47) that display good pharmacological 
properties such as efficacy, potency, and selectivity. VU10010 was discovered through 
optimizations of several hit compounds from a screen of compounds purchased from 
ChemBridge. Though VU10010 exhibits good efficacy, potency, and selectivity, it has solubility 
issues and low brain penetration. Its optimization leads to VU0152099 and VU0152100, which 
also display good efficacy, potency, and selectivity. In addition to those properties, they also 
exhibit higher brain penetration. However, because they are rapidly metabolized leaving only 
less than 10% of the parent compound remaining in rat and human liver microsomes, they 
became less attractive tool compounds. Therefore, optimization of VU0152100 is necessary to 
improve its pharmacological and pharmacokinetic properties. Among the initial hits, 1 was also 
found to have micromolar potency as an M4 PAM (Figure 48). We further explored this hit in 
conjunction with optimization of VU0152100. 
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VU10010   VU152099    VU0152100 
     
N S HN
O
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O
 
EC50: 400 nM    EC50: 403 nM    EC50: 380 nM 
Figure 47. M4 PAMs developed at Vanderbilt. 
 
 
1 
Figure 48. Hit from initial PAM screen. 
 
 Optimization of 1 occurs with derivation of the amide portion and the central core. 
Diversity-oriented synthesis is utilized to generate a library of compounds carrying the same 
central core as 1 and diversified amides. Of the analogs tested, short aliphatic chains are more 
tolerable than long chains and branched chains. Small cyclized aliphatic groups have better 
potencies compared to larger ones, especially cyclopropane (VU0409095). Nitrogen containing 
rings are very well tolerated (VU0409523 and VU0409524). Their potencies are comparable to 
that of 1 (EC50 1.7 µM). Substitution of other aromatic amides results in no activity. 
Replacement of the methoxymethyl benzothiazole central core with a truncated core 
(benzothiazole) and thiazolopyridine core generates analogs with no activity. When 
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methoxymethyl benzothiazole is replaced with hydroxymethyl benzothiazole, micromolar 
potency is retained in a few analogs. 
 Of those analogs generated for the optimization of 1, a few displayed comparable potencies 
(Figure 49). 
 
      
 VU0409524-2              VU0409095-1       VU0409523-1     
 EC50: 1.12 µM     EC50: 4.6 µM   EC50: 2.48 µM 
Figure  49. Some of the best analogs of 1 with comparable potencies. 
  
 The VU0152100 optimization effort includes replacement of the central core with 
bromocyclopropyl thienopyridine and chlorodimethyl thienopyridine. All analogs carrying the 
bromocyclopropyl thienopyridine core are inactive, with the exception of cyclopropyl amide. As 
for analogs generated using chlorodimethyl thienopyridine, most display micromolar to 
nanomolar potency. Notable ones are listed below. In comparison to VU0152099 and 
VU0152100, some chlorodimethyl thienopyridine analogs display better potencies (Figure 50). 
One clear trend exhibits among the functionalized nitrogen rings. As nitrogen is moved from 2- 
to 3- to 4-position on pyridines, potency increases. 
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VU0152099 
EC50: 403 
Fold shift: 26 
VU0152100 
EC50: 380 
 
VU0448057 
EC50: 56.9 
Fold shift: 7.6 
VU0448098 
EC50: 117 
 
Figure 50. Analogs of VU0152099 and VU0152100. 
 
Other notable compounds are listed below with their potency, fold shift and selectivity. 
Structure VU Number ECmax EC50 (nM) 
Fold 
shift 
Selective 
for M4 
 
VU0452032-1 ---- 293 
---- ---- 
 
VU0452129-1 ---- 94.9 55 Yes 
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VU0448088-1 93 40.0 139 Yes 
 
VU0449033-1 ---- 19.4 380 M4, M1, M2 
 
Figure 51. Other notable compounds with better potencies compared to VU0152100. 
 
In comparison to VU0152099 and VU0152100, the analogs generated using the 
chlorodimethyl thienopyridine core are more potent and have better fold shifts. A couple of 
examples are VU0449033 and VU0448088, which have potencies that are more than 10 fold 
better than VU0152100 (Figure 51). They are both able to shift the ACh concentration response 
curve leftward more than 10 fold compared to VU0152100. Their lipophilicity values (clogP) are 
less than those of VU0152099 and VU0152100, which could contribute to their greater 
solubility. Further structure activity relationship studies are needed to fully characterize these 
analogs to confirm that they have better pharmacological and pharmacokinetic profiles. 
Additional chemical modifications can be made to fully flush out the SAR to help better 
understand the functional groups tolerated and their binding modes. Modifications can range 
from reversing the amide linker to derivatizing the substituents of the central core to increase its 
functionality, alkylating the primary amine flanking the core, and tying the amine to the core 
forming three fused heterocyclic rings. These modifications are not only necessary for probing 
the binding pocket, but it is also necessary for optimizing pharmacological properties. Other 
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characterizations such as competitive radioligand binding and G-protein binding affinity have to 
be assessed to further prove the allosteric properties of these analogs. Good M4 tool compounds 
with ideal pharmacological and pharmacokinetic profile are needed to further elicit the role of 
M4 in schizophrenia.  
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Chapter IV 
 
MATERIALS and METHODS 
 
Medicinal Chemistry 
M4 PAM Synthesis 
Amide coupling general procedure. To a solution of carboxylic acid and amine in solvent, base 
and catalysts were added. The solution was stirred at room temperature overnight. Then the 
reaction was concentrated on a heating block. Each compound was purified via liquid 
chromatography/mass spectrometry purification system (Gilson) or flash chromatography system 
(ISCO Combiflash Rf). Purity is verified via liquid chromatography/mass spectrometry system 
(LCMS) and nuclear magnetic resonance ( NMR). 
Synthesis of thieno pyridine carboxylic acid core. To a solution of commercially available 2,5-
dichloro-2,6-dimethyl nicotinonitrile in ethanol (1M) in a microwave vial, methyl thioglycolate, 
and 5M LiOH or NaOH were added. The reaction was heated to 125°C for 20 minutes. The 
cyclized product was confirmed via LCMS. The lithium salt carboxylate product was protonated 
with 1M hydrochloric acid (HCL) solution. HCl was added until the pH of the reaction reaches 1. 
 
Pharmacology: All of the below in vitro procedures are adopted from Alice Rodriguez from Dr. 
Jeff Conn’s lab. The behavioral assay protocol is adopted from Analisa Thompson from Carrie 
Jones’s lab. 
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M4 in vitro Functional Assay. The human M4 cDNA in pcDNA3.1 (+) was purchased from 
www.cDNA.org. CHO cells purchased from the ATCC (www.atcc.org), were stably transfected 
with hM4 cDNA along with the chimeric G protein Gqi5 (Conklin et al., 1993) in pIREShygro 
(Invitrogen, Carlsbad, CA). Single hygromycin- and neomycin-resistant clones were isolated and 
screened for M4-mediated calcium mobilization. CHO cells expressing human M4 receptor were 
plated (Greiner Bio-One, Monroe, North Carolina) at 15,000 cells/20µL well in assay media 
(20mM HEPES, 10% FBS, Ham’s F-12). The plates were incubated overnight at 37°C in 5% 
CO2. Media was removed and assay buffer (10mL of 1M HEPES, HBSS, 2.5 mM Probenecid) 
containing 8uL of Fluo4-AM dye (Invitrogen), and 8uL of pluronic acid was added. Cells were 
incubated for 45 minutes at 37°C in 5% CO2 to allow for dye loading. Dye was removed, and 
45uL of assay buffer was added to each well. The plate is allowed to incubate in the dark at room 
temperature for 10-15 minutes. After incubation, the cell plates were loaded into Flexstation II 
(Molecular Device Corp). Test compound in assay buffer was added at 19 seconds. Then at 109 
seconds, a submaximal concentration of acetylcholine was added. Negative control was 
compound vehicle (0.2% DMSO) plus assay buffer; positive control was ACh CRC and positive 
control compounds that previously yielded maximal acetylcholine response. Fold shifts were 
determined using the same functional assay by varying the amount of acetylcholine in the 
presence of either a concentration of compound (10 µM) or vehicle. A concentration response 
curve was generated using acetylcholine concentrations ranging from 10pM to 100 µM. Assays 
were performed in triplicate on different days. Concentration response curves were generated 
using GraphPad Prism 4.0. 
 
Fold Shift Protocol 
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Cell line creation and culture of the human M4/Gqi5/CHO line.  The human M4 (hM4) cDNA 
in pcDNA3.1 (+) was purchased from www.cDNA.org. CHO cells purchased from the ATCC 
(www.atcc.org), were stably transfected with hM4 cDNA along with the chimeric G protein Gqi5 
(Conklin et al., 1993) in pIREShygro (Invitrogen, Carlsbad, CA) and single hygromycin- and 
neomycin-resistant clones were isolated and screened for M4-mediated calcium mobilization 
using the method described below. hM4/CHO-Gqi5 cells were cultured in Ham’s F-12; 10% FBS, 
20mM HEPES, 50µg/mL G418 (Mediatech, Inc., Herndon, VA), 500 µg/ml Hygromycin. All 
cell culture reagents were purchased from Invitrogen Corp. (Carlsbad, CA) unless otherwise 
noted. 
Fold-Shift Assay. Assays were performed within the Vanderbilt Center for Neuroscience Drug 
Discovery’s Screening Center. Human M4/Gqi5/CHO cells (15,000 cells/20 µL/well) were plated 
in black-walled, clear-bottomed, TC treated, 384 well plates (Greiner Bio-One, Monroe, North 
Carolina) in Ham’s F-12, 10% FBS, 20 mM HEPES. The cells were grown overnight at 37 °C in 
the presence of 5% CO2. The next day, the medium was removed and replaced with 20 µL of 2.3 
µM Fluo-4, AM (Invitrogen, Carlsbad, CA) prepared as a 2.3 mM stock in DMSO and mixed in 
a 1:1 ratio with 10% (w/v) pluronic acid F-127 and diluted in Assay Buffer (Hank’s balanced 
salt solution, 20 mM HEPES and 2.5 mM Probenecid (Sigma-Aldrich, St. Louis, MO)) for 45 
minutes at 37 °C.  Dye was removed and replaced with 20 µL of Assay Buffer. Test compounds 
were prepared in Assay Buffer to generate a 2x stock in 0.6% DMSO (0.3% final). 
Acetylcholine concentration responses were prepared at a 5X stock solution in assay buffer prior 
to addition to assay plates.  Ca2+ mobilization was measured at 37 degrees C using a Functional 
Drug Screening System 6000 (FDSS6000, Hamamatsu, Japan) kinetic plate reader according to 
the following protocol. Cells were preincubated with test compound (or vehicle) for 144 seconds 
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prior to the addition of a concentration response of the agonist ACh and the fluorescence was 
monitored for a total of 5 min. The signal amplitude was first normalized to baseline and then as 
a percentage of the maximal response to acetylcholine.  EC50 values for ACh in the presence of 
vehicle or compound were determined using GraphPad Prism (4.0c), which fits curves using 
standard non-linear regression (variable slope). Fold-Shift values were calculated by dividing the 
ACh EC50 in the presence of 10 µM compound by the ACh EC50 in the presence of vehicle. 
Compounds showing greater than a 3-fold shift were assigned 'Outcome' = 'Active', ‘Fold-Shift’ 
=’Value’, and ‘% ACh max’ = Value’. 
In vivo Pharmacology 
All experiments were conducted in accordance with the National Institutes of 
Health regulations of animal care covered in Principles of Laboratory Animal Care 
 
Drugs 
d-Amphetamine hemisulfate (AMPH) was obtained from Sigma (Cat#A5880-1G; St. Louis, 
MO). Salt-correction was used to determine the correct amount of the d-amphetamine 
hemisulfate form in mg to add to sterile water in order to yield a 1 mg/ml solution; injected with 
a volume equal to the body weight of each animal.  VU0448088 was formulated in volumes 
specific to the number of animals dosed each day. The appropriate amount according to the 
dosage was mixed into a 10% Tween 80 in sterile water solution. Each mixture was vortexed 
with  for 2-3 min and then sonicated in a 40˚C sonication bath for 45 min until in a solution or a 
very fine microsuspension. Next, the pH of all solutions was checked using 0-14 EMD pH strips 
and adjusted to a pH of 6-7 if necessary with 1N NaOH.  
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Animals 
Animals were housed in the animal care facility certified by the American Association for the 
Accreditation of Laboratory Animal Care (AAALAC) under a 12-hour light/dark cycle (lights 
on: 7 a.m.; lights off: 7 p.m.) and had free access to food and water. The animals used in this 
experiment were food-deprived the evening before experimentation for oral administration of 
test compound. For enrichment purposes, animals were housed 2-3 per cage. The experimental 
protocols performed during the light cycle were approved by the Institutional Animals Care and 
Use Committee of Vanderbilt University and conformed to the guidelines established by the 
National Research Council Guide for the Care and Use of Laboratory Animals. 
Amphetamine-induced Hyperlocomotion 
Male Harlan Sprague Dawley rats (Harlan Laboratories, Indianapolis, IN) were habituated in the 
locomotor activity test chambers for 30 min. Animals were next pretreated for an additional 30 
min with either vehicle or a dose VU0448088, i.p. followed by a subcutaneous injection of 1 
mg/kg amphetamine or vehicle and monitored for an additional 60 min. Changes in locomotor 
activity were recorded for a total of 120 min. Data were expressed as changes in ambulation 
defined as the total number of photobeam breaks per 5 min interval.   
Behavioral Data Analysis 
Behavioral data were analyzed using a one-way ANOVA with main effects of treatment and 
time. Post hoc analyses were performed using a Dunnett’s t-test with all treatment groups 
compared to the Vehicle+AMPH group using JMP ® 9.0 (SAS Institute, Cary, NC) statistical 
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software.  Data were graphed using SigmaPlot for Windows Version 11.0 (Saugua, MA). A 
probability of p ≤ 0.05 was taken as the level of statistical significance. 
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